Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 27908594

Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet Oncol
Publication date
2017 Jan
First author
Swisher EM

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2017 Jan;18(1):8-9. doi: 10.1016/S1470-2045(16)30621-0.
    note
    Source null
    related pmid
    27908593
    relationship
    Comment in
  2. citation
    Nat Rev Clin Oncol. 2017 Feb;14(2):71. doi: 10.1038/nrclinonc.2016.207.
    note
    Source null
    related pmid
    27958296
    relationship
    Comment in

Authors and identifiers

  1. name
    Swisher EM
    type
    Author
  2. name
    Lin KK
    type
    Author
  3. name
    Oza AM
    type
    Author
  4. name
    Scott CL
    type
    Author
  5. name
    Giordano H
    type
    Author
  6. name
    Sun J
    type
    Author
  7. name
    Konecny GE
    type
    Author
  8. name
    Coleman RL
    type
    Author
  9. name
    Tinker AV
    type
    Author
  10. name
    O'Malley DM
    type
    Author
  11. name
    Kristeleit RS
    type
    Author
  12. name
    Ma L
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Swisher EM
    type
    Author
  2. name
    Lin KK
    type
    Author
  3. name
    Oza AM
    type
    Author
  4. name
    Scott CL
    type
    Author
  5. name
    Giordano H
    type
    Author
  6. name
    Sun J
    type
    Author
  7. name
    Konecny GE
    type
    Author
  8. name
    Coleman RL
    type
    Author
  9. name
    Tinker AV
    type
    Author
  10. name
    O'Malley DM
    type
    Author
  11. name
    Kristeleit RS
    type
    Author
  12. name
    Ma L
    type
    Author
bibliography ids
  1. nci-bib-d645d29d6a46f54e7f830977
book metadata
content sha256
ae791574375c88dce6632d25767763847e868a4519a4e6db394d1fb70a5ae59c
document type
citation
dois
  1. 10.1016/S1470-2045(16)30559-9
electronic publication date
display
2016 Nov 29
precision
day
year
2016
evidence scope
bibliographic_metadata_only
id
pubmed:27908594
immutable id
pubmed:27908594@ae791574375c88dce6632d25767763847e868a4519a4e6db394d1fb70a5ae59c
journal
abbreviation
Lancet Oncol
issn electronic
1474-5488
issn print
1470-2045
issue
1
name
The Lancet. Oncology
nlm unique id
100957246
pages
75-87
volume
18
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2017 Jan;18(1):8-9. doi: 10.1016/S1470-2045(16)30621-0.
    note
    Source null
    related pmid
    27908593
    relationship
    Comment in
  2. citation
    Nat Rev Clin Oncol. 2017 Feb;14(2):71. doi: 10.1038/nrclinonc.2016.207.
    note
    Source null
    related pmid
    27958296
    relationship
    Comment in
outcomes validated
false
pmid
27908594
provenance
batch id
7a1288ac8bb5f9826304
provider
NCBI PubMed ESummary
record sha256
e63b92399f7de5f04a710a2dbf6c193251f11ec8d92181151f614b816c338e87
response sha256
0e879bec8c19d1cfda5629dca8745b04155d18cf54361825d4c070aebad2984d
retrieved at
2026-09-09T23:47:23.138359+00:00
publication date
display
2017 Jan
precision
month
year
2017
publication types
  1. Clinical Trial, Phase II
  2. Journal Article
  3. Multicenter Study
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/27908594/
title
Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.

Preserved source evidence · Not medical advice